Advances in mRNA Cancer Vaccines: Mechanisms, Clinical Progress and Future Outlook

Authors

  • Fengyi Hou Holy Trinity Catholic Secondary School, Oakville, Ontario, Canada

DOI:

https://doi.org/10.54097/kym0as08

Keywords:

mRNA cancer vaccines; cancer immunotherapy; personalized neoantigen vaccines; lipid nanoparticle delivery.

Abstract

Despite significant advances, cancer continues to be a serious burden to the world and the lack of effectiveness of conventional therapies has encouraged the exploration of new immunotherapeutic strategies. mRNA cancer vaccines are one of these that are an attractive approach due to the speed of their design, their high immunogenicity and the potential of personalized treatment. The present review outlines the biology of mRNA cancer vaccines, such as tumor antigens, mechanisms of immune escape and immune activation of the vaccines. Novel developments in lipid nanoparticle (LNP) delivery systems, lymph node targeting strategies, and preclinical development are discussed. In addition, existing clinical data from melanoma, lung cancer, breast cancer, pancreatic cancer, and other cancers are explored, including the exciting results from the KEYNOTE-942 trial. Lastly, key challenges related to tumor heterogeneity, delivery efficiency, manufacturing complexity, and regulatory considerations are analyzed together with future directions involving personalized neoantigen vaccines, AI-driven vaccine design, and next-generation delivery technologies. In conclusion, mRNA cancer vaccines are a rapidly developing field and hold great promise in reshaping the future of precision cancer immunotherapies.

Downloads

Download data is not yet available.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: https://doi.org/10.3322/caac.21834

[2] World Health Organization. Cancer [Internet]. Geneva: World Health Organization, 2024 [cited 2026 Jun 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.

[3] Sayour EJ, Boczkowski D, Mitchell DA, et al. Cancer mRNA Vaccines: Clinical Advances and Future Opportunities. Nat Rev Clin Oncol, 2024, 21(7): 489-500. DOI: https://doi.org/10.1038/s41571-024-00902-1

[4] Weber JS, Carlino MS, Khattak MA, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet, 2024, 403(10427): 632-644. DOI: https://doi.org/10.1016/S0140-6736(23)02268-7

[5] Hou X, Zaks T, Langer R, et al. Lipid Nanoparticles for mRNA Delivery. Nat Rev Mater, 2021, 6: 1078-1094. DOI: https://doi.org/10.1038/s41578-021-00358-0

[6] Liu X, et al. mRNA Cancer Vaccines: Construction and Boosting Strategies. ACS Nano, 2023, 17(20): 19550-19580. DOI: https://doi.org/10.1021/acsnano.3c05635

[7] Shariati A, et al. mRNA Cancer Vaccines from Bench to Bedside: A New Era in Cancer Immunotherapy. Biomark Res, 2024, 12: 141. DOI: https://doi.org/10.1186/s40364-024-00692-9

[8] Chen J, Ye Z, Huang C, et al. Lipid Nanoparticle-Mediated Lymph Node-Targeting Delivery of mRNA Cancer Vaccine Elicits Robust CD8+ T Cell Response. Proc Natl Acad Sci U S A, 2022, 119(34): e2207841119. DOI: https://doi.org/10.1073/pnas.2207841119

[9] Yaremenko AV, et al. Clinical Advances of mRNA Vaccines for Cancer Immunotherapy. Med, 2025, 6(1). DOI: https://doi.org/10.1016/j.medj.2024.11.015

[10] Laila UE, Wang A, Xu ZX. Emerging Prospects of mRNA Cancer Vaccines: Mechanisms, Formulations, and Challenges in Cancer Immunotherapy. Front Immunol, 2024, 15. DOI: https://doi.org/10.3389/fimmu.2024.1448489

[11] Wang B, Pei J, Xu S, et al. Recent Advances in mRNA Cancer Vaccines: Meeting Challenges and Embracing Opportunities. Front Immunol, 2023, 14. DOI: https://doi.org/10.3389/fimmu.2023.1246682

[12] Tenchov R, Bird R, Curtze AE, et al. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano, 2021, 15(11): 16982-17015. DOI: https://doi.org/10.1021/acsnano.1c04996

[13] ClinicalTrials.gov. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 in Advanced Non-Small Cell Lung Cancer. NCT05142189.

[14] Wang Y, Zhang Z, Luo J, et al. mRNA Vaccine: A Potential Therapeutic Strategy. Mol Cancer, 2021, 20: 33. DOI: https://doi.org/10.1186/s12943-021-01311-z

[15] Qu Y, Xu J, Zhang T, et al. Advanced Nano-Based Strategies for mRNA Tumor Vaccines. Acta Pharm Sin B, 2024, 14: 170-189. DOI: https://doi.org/10.1016/j.apsb.2023.07.025

[16] Magoola M, Niazi SK. Current Progress and Future Perspectives of RNA-Based Cancer Vaccines. Cancers, 2025, 17(11): 1894. DOI: https://doi.org/10.3390/cancers17111882

[17] Alshehry Y, Liu X, Li W, et al. Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy. AAPS J, 2025, 27: 66. DOI: https://doi.org/10.1208/s12248-025-01051-8

[18] Asthana GS, Bhattacharjee S, Kumar J, et al. Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy. Adv Immunol, 2025, 166: 37-75. DOI: https://doi.org/10.1016/bs.ai.2025.02.001

[19] Yang Y, Zhang X, Li J, et al. mRNA Vaccine Platforms and Novel Delivery Systems. Hum Vaccin Immunother, 2025.

[20] BioNTech SE. BNT116-01: A Trial Evaluating BNT116 in Patients with Non-Small Cell Lung Cancer. BioNTech Clinical Trials, 2025.

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Hou, F. (2026). Advances in mRNA Cancer Vaccines: Mechanisms, Clinical Progress and Future Outlook. International Journal of Biology and Life Sciences, 17(2), 72-78. https://doi.org/10.54097/kym0as08